#EHA2024: Early-phase trials in AML

To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Hybrid Congress, we have collated our social media coverage. Catch up here with our live social media relating to early-phase trials in acute myeloid leukemia (AML).

CONGRESS | #EHA2024
Naval Daver @Daver_Leukemia @MDAndersonNews presents the first-in-human phase I/II trial of the menin-MLL inhibitor DSP-5336 in patients with R/R AML.
▪️ No DLTs observed to date (n=57)
▪️ TRAEs seen in ≥10% patients were vomiting (17.5%), nausea (12.3%);… pic.twitter.com/GsBuYgXhyJ

— AML Hub (@AML_Hub) June 14, 2024

CONGRESS | #EHA2024
Andrew Wei @PeterMacCC discusses results from a phase Ib trial showing that the menin-KMT2A inhibitor bleximenib (JNJ-75276617) in combination with Ven-Aza was tolerable and clinically active in 60 patients with KMT2Ar/NPM1m R/R AML, including those with prior… pic.twitter.com/WON0AoBb2p

— AML Hub (@AML_Hub) June 14, 2024

CONGRESS | #EHA2024
Joshua Zeidner @LeukDocJZ @UNC_Lineberger presents interim results from a phase Ib dose-escalation trial of the triplet of revumenib plus Ven-Aza in older patients with ND KMT2Ar/NPM1m AML, a substudy within the Beat AML Master Trial.
▪️ Revumenib-Ven-Aza… pic.twitter.com/O5pyKXsLRZ

— AML Hub (@AML_Hub) June 14, 2024

CONGRESS #EHA2024 | Leo Ruhnke @leoruhnke @Medizin_TUD presents updated results of the phase I/II SAL RELAX trial (NCT04330820), evaluating the combination of venetoclax with high dose cytarabine and mitoxantrone in pts with R/R AML (N=55). The primary endpoint was met, with CRc… pic.twitter.com/EI2I7WOisg

— AML Hub (@AML_Hub) June 15, 2024

CONGRESS #EHA2024 | @AlexBataller @MDAndersonNews presents findings of a phase I/II study (NCT05010122) evaluating safety and efficacy of a fully oral combination of decitabine/cedazuridine with venetoclax and gilteritinib in pts with ND or R/R AML or #MDS with FLT3 mutations… pic.twitter.com/ArYpXj4vs4

— AML Hub (@AML_Hub) June 15, 2024

CONGRESS #EHA2024 | Sylvain Garciaz @GarciazSylvain, @paoli_calmettes, presents findings of the phase I portion of an ongoing phase I/II trial (NCT05086315) investigating SAR443579, a CD123 NK cell engager, in adults with R/R AML or HR #MDS (N=59). The toxicity profile was… pic.twitter.com/kZzJvuagTR

— AML Hub (@AML_Hub) June 16, 2024

CONGRESS | #EHA2024 | Poster
Dominik Chraniuk, MICS Medical Center Toruń, presents initial findings from the phase II RIVER-52 trial of RVU120, a first-in-class oral CDK8/19 kinase inhibitor, in patients with R/R AML and HR-MDS.

RVU120 250 mg EOD was shown to be safe and… pic.twitter.com/6TbLayGqws

— AML Hub (@AML_Hub) June 17, 2024

CONGRESS | #EHA2024 | Poster
Tapan Kadia @TapKadia, @MDAndersonNews, presents findings of a phase II study evaluating cladribine, idarubicin, and higher dose cytarabine (CLIA) in pts with R/R AML (N=98).
▪️ After 1-2 courses to best response, ORR (CR/CRi) was 42% of whom 61% pts… pic.twitter.com/BkkLmFx6ox

— AML Hub (@AML_Hub) June 18, 2024

CONGRESS | #EHA2024 | Poster
Neerav Shukla, @MSKCancerCenter, presents findings of AUGMENT-102 trial (NCT05326516) evaluating safety, preliminary activity, and recommended phase II dose of revumenib in combination with fludarabine/cytarabine in pts with R/R AML (N=27). Dose level… pic.twitter.com/8jObg8I2NG

— AML Hub (@AML_Hub) June 18, 2024

CONGRESS #EHA2024 | Gautam Borthakur @GBorthakur, @MDAndersonNews, presents prospective outcomes of a phase II trial (NCT00801489) evaluating the combination of FLAG with gemtuzumab (FLAG-GO) vs idarubicin (FLAG-IDA) in pts with ND CBF-AML. In pts with de novo CBF AML (n=179):
▪️… pic.twitter.com/otQhK1ud42

— AML Hub (@AML_Hub) June 16, 2024

CONGRESS | #EHA2024
Jorge E Cortes @GCC_Cortes @GACancerCenter presents final 5-year findings of a phase II trial (NCT02719574), demonstrating the efficacy and durability of the IDH1 inhibitor olutasidenib at 150mg BID in patients with IDH1m AML.
▪️ In 147 patients, the primary… pic.twitter.com/z6Hu4fevZL

— AML Hub (@AML_Hub) June 15, 2024

CONGRESS #EHA2024 | Late-breaking | Stine Ulrik Mikkelsen @Rigshospitalet presents results from the phase II EVI-2 trial (NCT03682029), investigating safety and efficacy of oral vit C 1000mg/day supplementation, vs placebo, in pts with low-risk myeloid malignancies (N=109).
▪️… pic.twitter.com/Cx0vPICeXP

— AML Hub (@AML_Hub) June 16, 2024

CONGRESS | #EHA2024
Anne Sophie Kubasch @ASKubasch @UKL_Leipzig presented long-term data showing that MRD-guided pre-emptive treatment with Aza delayed relapse in patients with MRD-positivity in the phase II open-label RELAZA2 study in patients with MDS or AML.
▪️ After median… pic.twitter.com/EMTK6rVuaM

— AML Hub (@AML_Hub) June 20, 2024

CONGRESS #EHA2024 | Wei-Ying Jen @jenweiying @MDAndersonNews presents findings of a phase II trial evaluating FLAG-IDA in combination with venetoclax in pts with ND (n=68) or R/R (n=59) AML.
▪️ In pts with ND AML, ORR was 99%, with 96% achieving CRc, of whom 88% were MRD… pic.twitter.com/C7zGvErG7P

— AML Hub (@AML_Hub) June 15, 2024

CONGRESS | #EHA2024
Ghayas Issa @GhayasIssa @MDAndersonNews presents an interim analysis from the AUGMENT-101 trial showing revumenib monotherapy to be efficacious in 57 heavily pre-treated patients with KMT2Ar R/R AML.
▪️ After median follow-up of 6.1 months, 23% patients… pic.twitter.com/TTK7SsMHLo

— AML Hub (@AML_Hub) June 14, 2024